Skip to content

A Study on the Efficacy and Safety of Ciprofol in Painless Oocyte Retrieval

A Study on the Efficacy and Safety of Ciprofol in Painless Oocyte Retrieval

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600123888
Enrollment
Unknown
Registered
2026-04-30
Start date
2026-04-30
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility

Interventions

Ciprofol Group:Upon entering the operating room, the patient was assisted into the lithotomy position by nursing staff, followed by a three-part identity verification by the surgical team, anesthesiol

Sponsors

Qingdao Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. The patient meets the indications for painless egg retrieval and can tolerate the procedure: 2. ASA (American Society of Anesthesiologists patient condition classification) level I-II, the patient's age is between 20 and 45 years old, and the body mass index is 18.5 - 27.9 kg/m^2; 3. The patient has clear consciousness and can communicate and interact with the doctor. They can understand the visual analog scale method under the guidance of the doctor; 4. There is no history of cardiovascular diseases such as hypertension and coronary heart disease in the past; 5. No neurological or mental disorders; 6. No severe drug allergy history; 7. Preoperative liver and kidney functions are normal; 8. No serious blood system diseases; 9. No recent upper respiratory tract infection; 10. No alcohol addiction, no fat metabolism disorder.

Exclusion criteria

Exclusion criteria: 1. Those with a history of long-term use of narcotic analgesics, sedatives or non-steroidal anti-inflammatory drugs; 2. Those with polycystic ovary syndrome, or external genitalia with eczema or other skin diseases; 3. Patients with polycystic ovary syndrome; 4. Those with milk or egg allergies and other special medical histories; 5. Those with other factors that clearly affect embryo implantation: uterine malformations, pelvic effusion, intrauterine adhesions, endometrial polyps, submucosal fibroids or uterine fibroids that significantly compress the endometrium, etc.; 6. Those with endometriosis, ovarian chocolate cysts or ovarian cysts larger than 3 cm, with evidence of laparoscopy and/or ultrasound examination; 7. Both male and female patients have obvious autoimmune or endocrine diseases; 8. Patients with reproductive system tuberculosis; 9. Female patients whose egg retrieval was cancelled on the day of retrieval.

Design outcomes

Primary

MeasureTime frame
Incidence of involuntary body movements;

Secondary

MeasureTime frame
Drug concentrations of Ciprofol in follicular fluid across different follicle aspiration sequences;Drug concentrations of Propofol in follicular fluid across different follicle aspiration sequences;Drug concentrations of Butorphanol in follicular fluid across different follicle aspiration sequences;IL-6 levels in follicular fluid across aspiration sequences; Reactive oxygen species (ROS) levels in follicular fluid by aspiration sequence;Embryo quality parameters;Pregnancy outcome measures;Intraoperative vital signs;Patient comfort parameters;

Countries

China

Contacts

Public ContactRui Dong

Qingdao Municipal Hospital

dongrui@whu.edu.cn+86 532 8271 6868

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026